Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Return on Capital Employed (2016 - 2026)

Aytu Biopharma has reported Return on Capital Employed over the past 14 years, most recently at 14.98% for Q4 2025.

  • Quarterly Return on Capital Employed fell 248.0% to 14.98% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 14.98% through Dec 2025, down 248.0% year-over-year, with the annual reading at 13.48% for FY2025, 1103.0% down from the prior year.
  • Return on Capital Employed was 14.98% for Q4 2025 at Aytu Biopharma, down from 14.34% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 30.92% in Q1 2024 and troughed at 123.17% in Q2 2022.
  • The 5-year median for Return on Capital Employed is 13.57% (2025), against an average of 34.91%.
  • Year-over-year, Return on Capital Employed plummeted -7725bps in 2022 and then surged 11825bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 54.82% in 2021, then plummeted by -83bps to 100.6% in 2022, then skyrocketed by 111bps to 10.86% in 2023, then tumbled by -215bps to 12.49% in 2024, then decreased by -20bps to 14.98% in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Return on Capital Employed are 14.98% (Q4 2025), 14.34% (Q3 2025), and 12.8% (Q2 2025).